Assignee
EYEPOINT PHARMACEUTICALS INC
US·22 granted patents·9 pending applications·38 citations·filing 2018–2024
Top patents by PatentIndex Score
31 records- 0196US11180551B2Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)EYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Nov 23, 2021·6 cites·34 claims
- 0294US11253502B2Tie-2 activators targeting the Schlemm's canalEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Feb 22, 2022·3 cites·39 claims
- 0393US11873334B2Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGFEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Jan 16, 2024·2 cites·19 claims
- 0493US11613534B2Small molecule activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Mar 28, 2023·2 cites·13 claims
- 0592US12145986B2Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)EYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Nov 19, 2024·1 cites·20 claims
- 0692US11666558B2Methods of treating intraocular pressure with activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2021·Granted Jun 6, 2023·2 cites·10 claims
- 0790US11814425B2Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereofEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Nov 14, 2023·2 cites·10 claims
- 0886USD1037439SOcular injectorEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Jul 30, 2024·10 cites·1 claims
- 0986US12043664B2Methods for treating vascular leak syndrome and cancerEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Jul 23, 2024·1 cites·13 claims
- 1084US11413242B2Formulations of Tie-2 activators and methods of use thereofEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Aug 16, 2022·1 cites·26 claims
- 1183US12398204B2Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonistEYEPOINT PHARMACEUTICALS INC·Filed 2023·Granted Aug 26, 2025·0 cites·19 claims
- 1282US12152023B2Compositions, formulations and methods for treating ocular diseasesEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Nov 26, 2024·0 cites·18 claims
- 1382US2022378750A1Human protein tyrosine phosphatase inhibitors and methods of useEYEPOINT PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1479US12171751B2Methods of treating intraocular pressure with activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2023·Granted Dec 24, 2024·0 cites·20 claims
- 1578US2025082613A1Tie-2 activators targeting the schlemm's canalEYEPOINT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1677US12514823B2Bioerodible drug delivery devicesEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Jan 6, 2026·0 cites·11 claims
- 1776US12187715B2Small molecule activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2023·Granted Jan 7, 2025·0 cites·22 claims
- 1876USD1043969SOcular injectorEYEPOINT PHARMACEUTICALS INC·Filed 2023·Granted Sep 24, 2024·8 cites·1 claims
- 1974US12329859B2Bioerodible drug delivery devicesEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Jun 17, 2025·0 cites·17 claims
- 2074US12064420B2Tie-2 activators targeting the Schlemm's canalEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Aug 20, 2024·0 cites·16 claims
- 2169US2023139250A1Formulations of tie-2 activators and methods of use thereofEYEPOINT PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2267US11298323B2Bioerodible drug delivery devicesEYEPOINT PHARMACEUTICALS INC·Filed 2018·Granted Apr 12, 2022·0 cites·17 claims
- 2358US12544362B2Methods of treating acute respiratory distress syndrome with activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2021·Granted Feb 10, 2026·0 cites·18 claims
- 2458US2019201324A1Injectable sustained release delivery devicesEYEPOINT PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2556US2024190857A1Methods for manufacture of small molecule activators of tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2653US2025205152A1Method of preventing age-related macular degeneration by administering an ocular drug delivery insertEYEPOINT PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2752US2023103975A1Injector for delivering implantsEYEPOINT PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2851US12551368B2Bioerodible ocular drug delivery insert and therapeutic methodEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Feb 17, 2026·0 cites·14 claims
- 2951US2025186398A1Continuous dosing regimen for treatment of a condition of the eyeEYEPOINT PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3047USD1106444SOcular injectorEYEPOINT PHARMACEUTICALS INC·Filed 2024·Granted Dec 16, 2025·0 cites·1 claims
- 3145US2025186336A1Method of treating wet age-related macular degenerationEYEPOINT PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EYEPOINT PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →